14-Deoxy-11,12-didehydroandrographolide (AP10) has hypotensive, anti-inflammatory, anti-asthma, and anti-cancer actions. It can inhibit NF-κB activation.

A549 cells (3×10^3/well), BEAS-2B cells (5×10^3/well), and RBL-2H3 cells (3×10^3/well) are seeded in flat-bottomed 96-well plates overnight and then incubated with increasing concentrations (3-120 μM) of 14-deoxy-11,12-didehydroandrographolide for 24 and 48 h at 37°C. Cell viability is analyzed using the CellTiter 96 AQueous cell proliferation assay. Absorbance is recorded at 490 nm.

Female BALB/c mice, 6 to 8 weeks old, are sensitized and challenged with OVA. Briefly, mice are sensitized by ip injections of 20 μg of OVA and 4 mg of Al(OH)3 suspended in 0.1 mL of saline on days 0 and 14. On days 22, 23, and 24, mice are challenged with 1% OVA aerosol for 30 min. 14-deoxy-11,12-didehydroandrographolide (0.1, 0.5, and 1 mg/kg) or vehicle (1% DMSO) in 0.1 mL of saline is given by i.p injections 2 h before and 10 h after each OVA aerosol challenge.

AP10, 14-脱氧-11,12-二去氢穿心莲内酯, 14-dehydro Andrographolide

DMF: 100 mg/mL (300.82 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.02 mM), Sonication is recommended.